A man from Wisconsin, Tim Friede, has garnered attention for his extreme self-experimentation with snake venom over an 18-year period, during which he administered diluted venom injections 856 times. His unusual approach has led to significant findings in the development of a new drug that provides protection against bites from 19 different snake species, including some of the deadliest in Australia, such as the eastern brown snake and inland taipan.
Friede’s journey into the world of venom began around 2000 when he started collecting venomous snakes. Driven by a desire to build immunity, he began self-injecting venom in increasing doses. Early in this process, he experienced a severe incident where a bite from an Egyptian cobra left him in a coma for four days. Despite this, his persistence paid off; over time, he generated antibodies capable of neutralising various snake venoms.
Scientists, having discovered Friede’s extensive experimentation online, recognised the unique potential of his immune response. Jacob Glanville, CEO of Centivax, noted Friede’s extensive history of self-immunisation with venom from 16 highly lethal snake species, a feat that’s quite extraordinary. Upon agreeing to participate in research, it was found that Friede’s body had developed antibodies effective against multiple snake neurotoxins.
The research aimed to create a universal antivenom, leading scientists to compile a testing panel featuring 19 of the world’s most venomous snakes, predominantly from the elapid family. They successfully isolated specific antibodies from Friede’s blood that reacted positively to the neurotoxins of the tested species. Remarkably, the resulting antivenom proved to offer full protection against 13 of those species, with partial protection for an additional six.
The research team is now prepared to test this new antivenom cocktail in Australia, initially administering it to dogs that have suffered snake bites in veterinary clinics. There are also ongoing discussions about expanding the research to develop an antivenom for the viper family as well. Peter Kwong, a lead author and professor at Columbia University’s Vagelos College of Physicians and Surgeons, mentioned the possibility of creating a dual antivenom cocktail targeting both elapids and vipers, depending on the geographical distribution of snake species.
Friede’s unconventional contributions could lead to significant advancements in snakebite treatment, potentially providing a life-saving solution in regions affected by venomous snakes.